LONDON (Reuters) on a new drug from giants GlaxoSmithKlein:
An experimental drug that blocks certain brain receptors can reduce nicotine cravings in addicted rats and baboons - a finding researchers say could lead to new medicines to help people stop smoking for good.
The candidate drug, called GSK598809, belongs to a class of compounds that block a specific type of dopamine receptor in key areas of the brain linked to tobacco addiction.
[...]
Previous studies have shown that nicotine in tobacco smoke increases the release of the brain chemical dopamine in the ventral striatum, midbrain and pallidum - all parts of the brain thought to play a key role in getting smokers hooked.
Didn't they learn anything from Champix (other than that pharmaceutical drugs regardless of their track record are still considered to be a lower risk to health than smoking?)
